hpk1 inhibitor bgb-26808
Generic: Hpk1 Inhibitor BGB-26808
hpk1 inhibitor bgb-26808: 1 clinical trial tracked.
hpk1 inhibitor bgb-26808 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about hpk1 inhibitor bgb-26808, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Primary endpoint: Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
InterventionalRandomizedopen337 targetStarted 2023-09Completion 2029-0228 sites · Australia, China, New Zealand, United StatesBeOne Medicines